Your browser doesn't support javascript.
Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019.
Betton, Maureen; Livrozet, Marine; Planas, Delphine; Fayol, Antoine; Monel, Blandine; Védie, Benoit; Bruel, Timothée; Tartour, Eric; Robillard, Nicolas; Manuguerra, Jean-Claude; Blanchard, Anne; Ghosn, Jade; Visseaux, Benoit; Péré, Hélène; Lebeaux, David; Schwartz, Olivier; Veyer, David; Hulot, Jean-Sébastien.
  • Betton M; Université de Paris, Inserm, Paris-Centre de Recherche Cardiovasculaire (PARCC), Paris, France.
  • Livrozet M; Centre d'investigation clinique (CIC1)418 and Département médico-universitaire Cardiologie Rein Transplantation Neurovasculaire (DMU CARTE), Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France.
  • Planas D; Université de Paris, Inserm, Paris-Centre de Recherche Cardiovasculaire (PARCC), Paris, France.
  • Fayol A; Centre d'investigation clinique (CIC1)418 and Département médico-universitaire Cardiologie Rein Transplantation Neurovasculaire (DMU CARTE), Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France.
  • Monel B; Virus and Immunity Unit, Department of Virology, Institut Pasteur, Centre national de la recherche scientifique (CNRS) UMR 3569, Paris, France.
  • Védie B; Vaccine Research Institute, Faculté de Médecine, Inserm U955, Université Paris-Est Créteil, Créteil, France.
  • Bruel T; Université de Paris, Inserm, Paris-Centre de Recherche Cardiovasculaire (PARCC), Paris, France.
  • Tartour E; Centre d'investigation clinique (CIC1)418 and Département médico-universitaire Cardiologie Rein Transplantation Neurovasculaire (DMU CARTE), Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France.
  • Robillard N; Virus and Immunity Unit, Department of Virology, Institut Pasteur, Centre national de la recherche scientifique (CNRS) UMR 3569, Paris, France.
  • Manuguerra JC; Laboratoire de Biochimie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Blanchard A; Virus and Immunity Unit, Department of Virology, Institut Pasteur, Centre national de la recherche scientifique (CNRS) UMR 3569, Paris, France.
  • Ghosn J; Department of Immunology, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Visseaux B; Service de Microbiologie, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Péré H; Institut Pasteur, Cellule d'Intervention Biologique d'Urgence, Paris, France.
  • Lebeaux D; Centre d'investigation clinique (CIC1)418 and Département médico-universitaire Cardiologie Rein Transplantation Neurovasculaire (DMU CARTE), Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France.
  • Schwartz O; Infectious and Tropical Diseases Department, Hôpital Bichat Claude Bernard, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Veyer D; Université de Paris, Infection, Antimicrobien, Modélisation, Evolution (IAME), Inserm, Paris, France.
  • Hulot JS; Université de Paris, Infection, Antimicrobien, Modélisation, Evolution (IAME), Inserm, Paris, France.
Clin Infect Dis ; 73(6): e1337-e1344, 2021 09 15.
Article in English | MEDLINE | ID: covidwho-1411827
ABSTRACT

BACKGROUND:

Humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurs within the first weeks after coronavirus disease 2019 (COVID-19). Those antibodies exert a neutralizing activity against SARS-CoV-2, whose evolution over time after COVID-19 as well as efficiency against novel variants are poorly characterized.

METHODS:

In this prospective study, sera of 107 patients hospitalized with COVID-19 were collected at 3 and 6 months postinfection. We performed quantitative neutralization experiments on top of high-throughput serological assays evaluating anti-spike (S) and anti-nucleocapsid (NP) immunoglobulin G (IgG).

RESULTS:

Levels of seroneutralization and IgG rates against the ancestral strain decreased significantly over time. After 6 months, 2.8% of the patients had a negative serological status for both anti-S and anti-NP IgG. However, all sera had a persistent and effective neutralizing effect against SARS-CoV-2. IgG levels correlated with seroneutralization, and this correlation was stronger for anti-S than for anti-NP antibodies. The level of seroneutralization quantified at 6 months correlated with markers of initial severity, notably admission to intensive care units and the need for mechanical invasive ventilation. In addition, sera collected at 6 months were tested against multiple SARS-CoV-2 variants and showed efficient neutralizing effects against the D614G, B.1.1.7, and P.1 variants but significantly weaker activity against the B.1.351 variant.

CONCLUSIONS:

Decrease in IgG rates and serological assays becoming negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the ancestral strain and the D614G, B.1.1.7, and P.1 variants for at least 6 months in patients previously hospitalized for COVID-19. A weaker protection was, however, observed for the B.1.351 variant.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Variants Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Variants Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid